Intermittent Neurogenic Claudication Treatment With APERIUS® (INCA)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Medtronic Spinal & Biologics ECA
ClinicalTrials.gov Identifier:
NCT00887744
First received: April 23, 2009
Last updated: November 12, 2012
Last verified: November 2012
  Purpose

The primary purpose of the study is to measure the change in severity of symptoms and ability to function in every day activities in patients suffering from degenerative lumbar spinal stenosis after treatment with the Aperius® device.


Condition Intervention Phase
Spinal Stenosis
Device: Aperius® Percutaneous Interspinous Spacer
Phase 4

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Multicenter, Post Marketing Clinical Follow-up Study to Evaluate the Safety and Effectiveness of the Minimally Invasive Device APERIUS® in Degenerative Lumbar Spinal Stenosis With Symptomatic Neurogenic Intermittent Claudication

Resource links provided by NLM:


Further study details as provided by Medtronic Spinal & Biologics ECA:

Primary Outcome Measures:
  • Mean Percentage Change in Symptom Severity at 6 Weeks Compared to Baseline, Using the Patient Completed Zurich Claudication Questionnaire for Symptom Severity [ Time Frame: From baseline up to 6 weeks follow-up ] [ Designated as safety issue: No ]
    This score is based on seven questions (overall pain,pain frequency,pain in the back,pain in the leg,numbness,weakness,and balanced disturbance.The first 6 categories are scored 1 to 5 (none,mild,moderate, severe,very severe). Balance disturbance is scored in a 1-3-5 scale (None,sometimes,often).The symptom severity scale score is the unweighted mean of all answered items (missing scores are discarded) in the questionnaire. Scoring range= 1-5.The change is calculated as the scores at the later timepoint minus the earlier timepoint expressed in terms of percentage.

  • The Proportion of Patients Experiencing a Procedure or Device Related Serious Adverse Events During the First 7 Days Starting at the Surgical Procedure [ Time Frame: Starting at the surgical procedure till 7 days post-operatively ] [ Designated as safety issue: Yes ]

    Adverse events were to be summarized by proportion. All Adverse events occurring within the first 7 days after the surgical procedure were to be analyzed:

    • Day of the procedure until P+1 (where P refers to the day of the surgical procedure)
    • P+2 until P+7


Secondary Outcome Measures:
  • Mean Percentage Change in Symptom Severity at 12 Months Compared to Baseline, Using the Patient Completed Zurich Claudication Questionnaire for Symptom Severity [ Time Frame: From baseline up to 12 months follow up ] [ Designated as safety issue: No ]

    The Zurich Claudication questionnaire - Symptom Severity score is based on seven questions (overall pain,pain frequency,pain in the back,pain in the leg,numbness,weakness,and balanced disturbance.The first 6 categories are scored 1 to 5 (none,mild,moderate, severe,very severe). Balance disturbance is scored in a 1-3-5 scale (None,sometimes,often).This score is the unweighted mean of all answered items (missing scores are discarded). Scoring range= 1-5.

    The change is calculated as the scores at the later timepoint minus the earlier timepoint expressed in terms of percentage.


  • Mean Percentage Change in Physical Function at 12 Months Compared to Baseline, Using the Zurich Claudication Questionnaire [ Time Frame: From baseline up to 12 months ] [ Designated as safety issue: No ]

    The Zurich Claudication Questionnaire - Physical Function score is the unweighted mean of six physical function questions ranging from 1 to 4. The six Physical Function questions ask about walking distance and ability to walk for pleasure, for shopping, and for getting around the house or apartment and from bathroom to bedroom. If more than one item was missing, the scale score was also to be considered as missing. The possible range of this score is 1.0 to 4.0.

    The change is calculated as the scores at the later timepoint minus the earlier timepoint expressed in terms of percentage.


  • Mean Change in Quality of Life Score at 12 Months Compared to Baseline [ Time Frame: From baseline up to 12 months follow up ] [ Designated as safety issue: No ]
    The quality of life scale covers five dimensions of health: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 3 levels (no health problems,moderate health problems,extreme health problems). The distribution of the response of the patients in these five dimensions was to be studied.This descriptive system was converted into a weighted health state index with Min-max score = 0-100 and 100 as most optimal score. If one or more questions are left unanswered, the questionnaire is not scored.

  • Proportion of Patients Having Procedure and/or Device Related Events During the Complete 12 Month Follow-up Period. [ Time Frame: From baseline up to 12 months follow up ] [ Designated as safety issue: Yes ]

Enrollment: 162
Study Start Date: November 2006
Study Completion Date: March 2010
Primary Completion Date: May 2009 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Aperius Treatment Arm
Single Arm
Device: Aperius® Percutaneous Interspinous Spacer
Implantation of the Aperius® device
Other Name: Aperius®

Detailed Description:

The Intermittent Neurogenic Claudication Treatment with Aperius® (INCA) trial was designed as a multicenter single arm post-marketing study to evaluate the safety and effectiveness of the Aperius® in patients with degenerative lumbar stenosis with symptomatic neurogenic intermittent claudication.

One hundred fifty six patients with a history of Degenerative lumbar spinal stenosis (Lumbar level L1 to L5) at one or maximum 2 levels with symptoms of neurogenic intermittent claudication with or without back pain were included. All patients were followed for 12 months with visits at 48 hours, 7 days, 6 weeks, 6 and 12 months.

Primary effectiveness endpoint was assessed as the mean percentage change from baseline in Zurich Claudication Questionnaire for Symptom Severity at 6 weeks. Other effectiveness outcomes were percentage change in Zurich Claudication Questionnaire scores (ZCQ), Quality of laife Questionnaire scores (called EuroQuol 5D or EQ-5D), Visual Analogue Scale (VAS) pain scores (back, leg and buttock groin pain), pain medication and changes in walking distance from baseline to follow-up. Procedure and device related Serious Adverse Events were assessed throughout the complete 12 month follow-up period.

  Eligibility

Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • History of Degenerative Lumbar Spinal Stenosis (Lumbar spine level from L1 -L5), confirmed by Magnetic Resonance Imaging (MRI) at one or maximal two levels, with symptoms of intermittent neurogenic claudication.
  • Leg / Buttock / Groin pain, with or without back pain, relieved by flexion. If back pain is also present, it must be partially relieved when flexed.
  • Able to sit for 50 minutes without pain.
  • Able to walk a distance of 20 meters without pain.
  • Patient states availability for and willing to perform all follow -up examinations.
  • Patient signed informed consent form.
  • Adults (minimum 21 years of age).

Exclusion Criteria:

  • Previous lumbar surgery.
  • Unremitting pain (leg/buttock/groin/back) in any spinal position.
  • Axial back pain without leg/buttock/groin pain.
  • Significant lumbar instability at the affected level: spondylolisthesis greater than grade 1 on a scale from 1-4.
  • Objective motor deficit.
  • Significant peripheral neuropathy by nerve conduction velocity tests (peroneal and sural nerves) according to the investigator.
  • Cauda equina syndrome, defined as neural compression causing neurogenic bowel (rectal incontinence) or bladder dysfunction (retention or incontinence).
  • Spinal Stenosis with clinical symptoms at one or more levels outside the L1-L5 lumbar region.
  • Severe symptomatic Spinal Stenosis requiring immediate surgical decompression,according to the investigator or lumbar spinal stenosis at more than 2 levels.
  • Lumbar Spinal Stenosis, caused by tumors, metastasis or Paget's disease.
  • Vascular claudication and severe peripheral vascular disease. (Diminished dorsalis pedis or tibial pulses) that limits walking.
  • History of primary or secondary osteoporosis defined as a DXA scan (=dual energy x-ray absorptiometry) of the hip showing T-score (=the number of standard deviations above or below the mean for the patient's age, sex and ethnicity) of more than 2.5 standard deviation below the mean in the presence of one or more fragility fractures.
  • Active systemic infection or local infection at the level to treat.
  • Major Depression according to Diagnostic and Statistical Manual of Mental Disorders (DSM) IV criteria.
  • Dementia and/or inability to give informed consent.
  • Unable to complete the study.
  • Pregnancy and breastfeeding.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00887744

Locations
Belgium
Hospital Campus Middelheim
Antwerp, Belgium
Academic Hospital Sint-Jan Brugge-Oostende AV
Bruges, Belgium
Park Léopold Hospital
Brussels, Belgium
Notre Dame de Grace Hospital
Gosselies, Belgium
University Hospital Tivoli
La Louvière, Belgium
Hospital du Grand Hornu
Mons, Belgium
Germany
Gemeinschaftspraxis Königsallee (Privat Clinic)
Düsseldorf, Germany
University Hospital Erlangen
Erlangen, Germany
Klinik und Poliklinik für Orthopädie (Hospital)
Köln, Germany
Asklepios Hospital Lindenlohe
Schwandorf, Germany
Orthopädische Fachklinik Schwarzach (Hospital)
Schwarzach, Germany
United Kingdom
Woodend Hospital
Aberdeen, United Kingdom
Sponsors and Collaborators
Medtronic Spinal & Biologics ECA
Investigators
Study Director: E. Wuelfert, Pharm. Medtronic Spinal & Biologics
  More Information

No publications provided

Responsible Party: Medtronic Spinal & Biologics ECA
ClinicalTrials.gov Identifier: NCT00887744     History of Changes
Other Study ID Numbers: CIP-0001-AP
Study First Received: April 23, 2009
Results First Received: April 11, 2011
Last Updated: November 12, 2012
Health Authority: Belgium: Ethics Committee
Germany: Ethics Commission
United Kingdom: Research Ethics Committee

Keywords provided by Medtronic Spinal & Biologics ECA:
Degenerative Lumbar Spinal Stenosis
Neurogenic Intermittent Claudication
Interpinous Device
Percutaneous

Additional relevant MeSH terms:
Constriction, Pathologic
Spinal Stenosis
Intermittent Claudication
Pathological Conditions, Anatomical
Spinal Diseases
Bone Diseases
Musculoskeletal Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases
Cardiovascular Diseases
Signs and Symptoms

ClinicalTrials.gov processed this record on September 22, 2014